Jeremy Levin, Ovid CEO

Two years af­ter a ‘pos­i­tive’ re­sult tanked their stock, Ovid's Je­re­my Levin wins a part­ner for the PhI­II jour­ney

If Je­re­my Levin could do it over again, he says he would.

Two years ago, his com­pa­ny, Ovid Ther­a­peu­tics, re­leased the topline da­ta from …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.